Hengsai Bio received tens of millions of RMB in Pre-A round financing

Hengsai Bio is a tumor immunotherapy developer, mainly engaged in the R&D and industrialization of a new generation of individualized dendritic cell tumor vaccines (DC vaccines). Strong, safe and convenient DC vaccine products. Recently announced the completion of tens of millions of RMB Pre-A round of financing, led by Fuhui Ventures, followed by Hengyue Investment, and Mabo Capital as the exclusive financial advisor.

This article is reproduced from: https://www.itjuzi.com/investevent/13182426
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.